Skip to main content

Stent drug-eluting clopidogrel

CBE ID
0588
1.5 Project
Endorsement Status
1.0 New or Maintenance
1.1 Measure Structure
Previous Endorsement Cycle
Is Under Review
No
1.6 Measure Description

This measure identifies patients undergoing percutaneous coronary intervention (PCI) with placement of a drug-eluting intracoronary stent during the first 9 months of the measurement year, who filled a prescription for clopidogrel in the 3 months following stent placement.

    Measure Specs
      General Information
      1.7 Measure Type
      1.3 Electronic Clinical Quality Measure (eCQM)
      1.20 Types of Data Sources
      1.14 Numerator

      Patients in the denominator who filled prescription(s) for clopidogrel in the 3 months following placement of the drug-eluting intracoronary stent. ("Evidence suggests clopidogrel should be continued upwards of 1 year.")

      Time Window: 3 months after stent placement

      1.15 Denominator

      Patients who underwent PCI with placement of a drug-eluting intracoronary stent, during the first 9 months of the measurement year, excluding those with contraindications to clopidogrel

      Exclusions

      contraindications to clopidogrel

      Most Recent Endorsement Activity
      Measure Retired and Endorsement Removed Cardiovascular Project 2013-2014
      Initial Endorsement
      Last Updated
      Removal Date
      Steward Organization
      Resolution Health, Inc.
      Steward POC email
      aurel.iuga@wellpoint.com
                Public Comments